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Willow tree extracts have been recognised for their medicinal
properties since 3500 BC (Mahdi et al, 2006). In the mid-late 1800s,
a series of breakthrough investigations led to the isolation of
salicin, synthesis of acetylsalicylic acid, and patent of aspirin.
However, more than 100 years and 20 000þ scientific publications
later, aspirin remains an interesting enigma, in that, the scope of
biological activity and spectrum of clinical application for this
agent remains incompletely defined. Aspirin’s anti-carcinogenic
potential was originally described in rodent models, with the
Melbourne Colorectal Cancer Study credited with reporting the
first human observational data in 1988 (Kune et al, 1988). Since
then, the use of aspirin has been inversely associated with multiple
target organ malignancies (Cuzick et al, 2009). However, existing
data are not entirely consistent, with unresolved questions
regarding the dose, duration and follow-up period needed to fully
appreciate aspirin’s actual chemopreventive benefits. To address
these questions, Rothwell et al (2011) recently combined and
analysed data from eight randomised clinical trials of aspirin (dose
range 75–1200mg per day) vs placebo, conducted in patient
populations at increased risk for cardiovascular disease, wherein
the scheduled duration of intervention was at least 4 years. Salient
findings from the pooled analysis included a 21% reduction in
overall risk for death due to cancer (hazard ratio (HR)¼ 0.79, 95%
confidence interval (CI)¼ 0.68–0.92; P¼ 0.003) among subjects
assigned to the active vs placebo interventions. Notably, aspirin
therapy for at least 5 years resulted in even greater risk reduction
(30–40%), with persistent effects on cancer mortality extending
out to 20 years of follow-up (HR¼ 0.80; 95% CI¼ 0.72–0.88;
Po0.0001 for solid organ tumours). Stratification by dose did not
appreciably influence the observed risk estimates. In response to
this intriguing report, discussions regarding the routine aspirin
use for the primary purpose of favourably affecting cancer risk
have been re-invigorated. Aside some benefits in cancer mortality
seem to be apparent within 4 years, suggesting provocatively that
the humble aspirin could perhaps also stifle cancer growth
(Rothwell et al, 2011). However, despite the ever-mounting efficacy
data, residual concerns remain about the potential of aspirin-
associated adverse events. This issue continues to impede
recommendations for widespread cancer chemoprevention in
generally healthy adults (Jankowski and Hawk, 2006; Jankowski
and Hunt, 2008; Rothwell et al, 2011). Specifically as about
30% of the population may get cancer, there is a need for
prevention (Jankowski and Hawk, 2006). However, from estimates
by Rothwell et al (2011), only 20% of the latter group will derive a
chemopreventive benefit from aspirin. Furthermore, the serious
risks of aspirin, usually GI bleeding, are currently contentious,
ranging from 0.02 to 2% per year (Jankowski and Hawk, 2006;
Jankowski and Hunt, 2008; Rothwell et al, 2011). This could mean
that serious side effects from 10 years of aspirin chemoprevention
would range from 0.2 to 20%. At the higher end, the benefits of
chemoprevention would be nullified by the risks. The recent report
from Langley et al (2011) is potentially paradigm-shifting, as it
alludes to an improved risk benefit ratio for adjuvant aspirin
therapy for early cancers This area has to date received relatively
lesser attention compared with its chemopreventive potential. As
discussed by the authors, new insights into the mechanisms of
aspirin-mediated growth inhibition (such as altered endothelial
cell tubule formation resulting in decreased angiogenesis) may
afford unique advantages over other non-steroidal anti-inflamma-
tory drugs or selective COX-2 inhibitors for treating malignant
tumours. Other putative effects of COX-2 on apoptosis, invasion,
and immunoregulation (Ghosh et al, 2010) support targeting this
enzyme in advanced, adjuvant, or neoadjuvant chemotherapy
settings as well. Available observational data further suggest that
aspirin use vs non-use is associated with improved survival
following colorectal (Chan et al 2009) or breast cancer (Holmes
et al 2010) diagnosis. However, three small randomised, controlled
trials of aspirin (dose range 1000–2400mg per day) in combina-
tion with other anti-cancer therapies did not confirm the
anticipated survival benefit. Similarly, results from the recently
reported VICTOR Trial (Midgley et al 2010), which evaluated the
effects of rofecoxib (a selective COX-2 inhibitor) 20mg per day vs
placebo on overall survival among stages II and III colorectal
cancer patients who had undergone potentially curative surgery
and completed adjuvant chemotherapy (when indicated), also
failed to demonstrate a statistically significant advantage from the
active agent, although the intervention phase was terminated early
(median exposure time of 7.4 months) due to concerns regarding
increased cardiovascular toxicity.
Given the current evidence base, where should additional
resources be invested to decipher aspirin’s true anti-cancer
potential? As noted by Langley et al (2011), further investigation
of the benefits and harms associated with aspirin therapy in high-
risk subject cohorts (i.e., patients with newly diagnosed cancer or
established premalignant conditions) may permit re-calibration of
an ‘acceptable’ safety profile. Consideration of oncologic and non-
oncologic endpoints, relating to efficacy and toxicity, in all large
clinical trials also seems imperative. Ideally, these disparate
endpoints could be accurately measured and appropriately
*Correspondence: Professor JAZ Jankowski;
E-mail: janusz.jankowski@bnc.ox.ac.uk
or Dr PJ Limburg; E-mail: Limburg.paul@mayo.edu
British Journal of Cancer (2011) 105, 1105 – 1106
& 2011 Cancer Research UK All rights reserved 0007 – 0920/11
www.bjcancer.com
weighted to more appropriately summarise the aspirin’s total
impact on personal and/or public health. Specific to the adjuvant
therapy setting, broader use of molecular phenotyping to define
tumours that are likely to be most susceptible to aspirin exposure
(i.e., based on increased COX-2 expression) could improve the
response rate. Finally, further attempts to clarify the genetic
characteristics that differentiate aspirin responders from non-
responders may also be of merit. Several of these issues will be
directly assessed by ongoing prospective studies, such as the
AspECT aspirin chemoprevention trial as well as the ChOPIN
genetic trial (Moayyedi and Jankowski, 2010). It may even be
possible to predict who will get a response to aspirin, based upon
their genome.
In summary, the case for aspirin therapy continues to get
stronger. It may never be too late for aspirin adjuvant therapy,
even if chemoprevention is not feasible. However, more
well-designed randomised controlled trials are needed with
adequate follow-up time before definitive clinical recommendations
can be given.
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